Pfizer (PFE) Current Deferred Tax Assets (2010 - 2026)

Pfizer has disclosed Current Deferred Tax Assets across 17 years of filings, most recently posting $3.6 billion for Q1 2026.

• In Q1 2026, Current Deferred Tax Assets rose 23.72% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $3.6 billion (up 23.72% YoY), while the FY2025 annual figure was $4.0 billion, up 19.7% from the prior year.
• Current Deferred Tax Assets fell to $3.6 billion in Q1 2026, from $4.0 billion in the prior quarter.
• Over the last five years, Current Deferred Tax Assets for PFE reached as high as $4.2 billion in Q1 2024 and fell as low as $2.5 billion in Q4 2022.
• The 5-year median for Current Deferred Tax Assets is $3.6 billion (2022), against an average of $3.5 billion.
• Annual changes were most pronounced in 2022 — Current Deferred Tax Assets sank 34.38% — and 2023, when it soared 53.97%.
• A 5-year view of Current Deferred Tax Assets shows it stood at $3.6 billion in 2022, then grew by 11.21% to $4.0 billion in 2023, then declined by 16.69% to $3.3 billion in 2024, then advanced by 19.7% to $4.0 billion in 2025, then dropped by 9.55% to $3.6 billion in 2026.
• According to Business Quant data, Current Deferred Tax Assets over the past three periods registered $3.6 billion, $4.0 billion, and $3.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.